Preparing healthcare companies for success
in the value-based economy

Real Endpoints helps our clients gain competitive advantage in market access
based on three primary assets:

  • Insights from our close working relationships with biopharma and payers
  • Objective, data-driven proprietary tools that reflect market reality for
    biopharma therapies and diagnostics
  • Creative, deeply experienced, solution-oriented people

Client Login >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

Value-Based Dealmaker

Design and orchestrate value-based deals

RxScorecardTM

Guide strategic and development decisions with customized, interactive value framework

Payer Impact

Evaluate real-world budget impact by payer segment with transparent model

Hub ExcellenceTM

Maximize the impact of patient services programs via benchmarking and needs analysis

Reimbursement iQTM

Enhance impact of customer-facing representatives using 360˚analysis

Customer Gateway

Develop customized program to foster goodwill with customers

Communications
and Training

Address customer pain points with targeted materials; strengthen confidence and knowledge of reps via customized training

Advisory and
Market Research

Generate strategic recommendations — conduct qualitative and quantitative research

News and Events

Safer Harbor

by Steve Usdin

FDA guidance released on June 12 broadens a safe harbor that allows medical product manufacturers to communicate with payers, PBMs, formulary committees and similar entities. A primary goal is to make it easier to base payments on outcomes not mentioned on product labels, but there could be broader effects in the loosened restrictions oncommunications between medical product developers and payers.

June 15, 2018

BioCentury

news >

REPC Webinar: The Maturation of the Value-Based Deal

Roger Longman
Jane Barlow, MD

Real Endpoints LLC

We’ve seen an explosion of value-based deals: from 10 in 2015-2016 to 25 from 2017 to Q1 2018 (and we’re on pace for 30+ this year), according to the Real Endpoints database. But we’ve also had the time to see which deals from 2015-16 haven’t worked — and why. We will take a candid look at what’s worked and what hasn’t worked in value-based agreements -- as well as preview the drugs coming to market in 2018 that could benefit from value-based agreements.

May 17, 2018
12:00pm ET

event >

29th Annual Cancer Progress Conference

Panelist: Roger Longman

Real Endpoints LLC

Value & Pricing Redux – Does the Song Remain the Same?

May 8, 2018
4:15pm ET

New York, NY

event >

Part D Sour Spot

by Steve Usdin

A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.

April 9, 2018

BioCentury

news >

Recent Insights

view archive >

June 18, 2018

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?

Watch webinar >

March 26, 2018

“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. The credibility afforded by ICER’s independent status, and its inclusion of diverse stakeholder views in constructing its cost effectiveness analyses, are leading payers and PBMs to use the analyses to establish coverage criteria, determine formulary placement and negotiate discounts from drug manufacturers.

read full insight article >
Just a quick note of appreciation for your responsiveness throughout the Market Access training process.  Your follow-up on a range of issues was always immediate and the resolution was definitive.  That type of effort and support doesn’t go unnoticed by me.

National Business Director

Top 5 Pharma

We have never seen a diagnostic like this before – it gets right to the heart of the problem.

Senior Director

Specialty Access Solutions, Top 5 Pharma

The insights you provided via Hub Excellence were the most insightful and actionable market research I have ever received.

Director of Operations

Reimbursement and Patient Support Services, Top 20 Pharma

RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.

Chronis H. Manolis, RPh

Vice President, Pharmacy UPMC Health Plan

We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.

Jack Bailey

President , GlaxoSmithKline U.S.